Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1397 studies found for:    "Multiple sclerosis"
Show Display Options
Rank Status Study
1 Recruiting Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Primary-progressive Multiple Sclerosis
Interventions: Drug: estriol;   Other: Placebo;   Drug: Norethindrone;   Other: Progestin Placebo
2 Recruiting Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Intervention: Other: Brain MRI
3 Recruiting A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients
Conditions: Primary Progressive Multiple Sclerosis,;   Secondary Progressive Multiple Sclerosis;   Relapsing-remitting Multiple Sclerosis,;   Demyelinating Autoimmune Diseases,;   Nervous System Diseases
Interventions: Behavioral: Combined program;   Behavioral: Physiotherapy in private practice
4 Unknown  A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Relapse Free
Interventions: Drug: masitinib;   Drug: placebo
5 Recruiting A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
Conditions: Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Clinically Isolated Syndrome
Intervention:
6 Active, not recruiting A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Conditions: Multiple Sclerosis, Remittent Progressive;   Multiple Sclerosis, Primary Progressive;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: BIIB041 (fampridine)
7 Recruiting Oral Guanabenz for Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Intervention: Drug: Guanabenz
8 Recruiting Plasma Exchanges in Multiple Sclerosis (MS) Relapses
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Acute Relapsing
Interventions: Procedure: plasma exchange;   Procedure: sham exchanges procedure
9 Enrolling by invitation Idebenone for Primary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Drug: Idebenone
10 Completed Natalizumab Treatment of Progressive Multiple Sclerosis
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Natalizumab
11 Not yet recruiting Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);   Drug: Interferon-beta
12 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
13 Active, not recruiting Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: DAC-HYP
14 Completed Safety Study of BIIB033 in Subjects With Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BIIB033;   Drug: Placebo
15 Active, not recruiting A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Interventions: Drug: Fampridine;   Drug: Placebo
16 Completed Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention:
17 Active, not recruiting Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: XCEL-MC-ALPHA;   Drug: Placebo
18 Completed Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab;   Other: standard of care
19 Recruiting Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Conditions: Relapsing Remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Cognitive Deficits;   Motor Deficits
Intervention: Device: tDCS
20 Completed Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon-1beta (Betaseron, BAY86-5046)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years